An anti-RBD (SARS-CoV-2 Spike) antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

STE73-2E9 is a human antibody which binds RBD of SARS-CoV-2 Spike protein at the RBD-ACE2 interface. Thereby, it neutralizes (as an IgG) SARS-CoV-2 infection in vitro. It was identified using phage display technique and originated in a SARS-CoV-2-naïve antibody library (Bertoglio et al., 2021).


Supporting references

Link Tested on Impact factor Notes Publication date
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
Spike protein ACE2 Biophysical assay In vitro Antibody
in vitro binding assay; in vitro biophysical assay; Vero E6 cells; ACE2-positive Expi293F cells; Calu-3 cells; SARS-CoV-2 strain Münster/FI110320/1/2020 12.12

The antibody (as an IgG) bound RBD in vitro with an EC50 of 0.2 nM (and 0.925 nM binding affinity for the whole SARS-CoV-2 Spike protein). It was observed to bind at the RBD-ACE2 interface. The antibody (as an IgG) neutralized SARS-CoV-2 live virus with an IC50 of 0.43 nM in vitro.